SNDX-6352

DRUG3 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc.

Conditions

ARDSAdvanced cancerCOVIDCoronavirusCytokine Release SyndromeCytokine StormUnresectable Intrahepatic Cholangiocarcinoma

Phase 2

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

CompletedNCT04301778

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUnresectable Intrahepatic Cholangiocarcinoma

Start: 2021-08-24End: 2024-02-06Updated: 2026-03-13

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

TerminatedNCT04415073

Syndax PharmaceuticalsARDS, Coronavirus, COVID +2

Start: 2020-05-30End: 2020-07-13Updated: 2022-07-22

Unknown Phase

A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING SINGLE AND MULTIPLE DOSES OF SNDX-6352 OR PLACEBO ADMINISTERED BY INTRAVENOUS (I.V.) INFUSION

Active, not recruitingNL-OMON42865

Syndax Pharmaceuticals, Inc.Advanced cancer

Start: 2016-10-20Target: 52Updated: 2024-02-28

Related Papers

A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.

Journal of Clinical Oncology2023-06-012 citations